Review of tenofovir use in HIV-infected children

Pediatric Infectious Disease Journal

Volumn 34, Issue 4, 2015, Pages 383-391

  Aurpibul, Linda ^a   Puthanakit, Thanyawee ^b,c  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

children; HIV; tenofovir

Indexed keywords

ATAZANAVIR; DIDANOSINE; LOPINAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ARTICLE; BONE DENSITY; CHILD; CHILDHOOD DISEASE; DRUG FORMULATION; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS (TOPIC); MIXED INFECTION; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRUS RESISTANCE; ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; BONE; DRUG EFFECTS; DRUG UTILIZATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV INFECTIONS; KIDNEY; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADENINE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; BONE AND BONES; CHILD; CHILD, PRESCHOOL; DRUG UTILIZATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HIV INFECTIONS; HUMANS; KIDNEY; ORGANOPHOSPHONATES; TENOFOVIR; YOUNG ADULT;

EID: 84937632315     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000571     Document Type: Article

References (92)

1. Patel K, Hernan MA, Williams PL, et al.; Pediatric AIDS Clinical Trials Group 219/219C Study Team. Long-Term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: A 10-year follow-up study. Clin Infect Dis. 2008;46:507-515.
2. Baheti G, King JR, Acosta EP, et al. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. AIDS. 2013;27:221-225.
3. Pruvost A, Negredo E, Theodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53:1937-1943.
4. Robbins BL, Wilcox CK, Fridland A, et al. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy. 2003;23:695-701.
5. Baheti G, Kiser JJ, Havens PL, et al. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother. 2011;55:5294-5299.
6. Viread: Highlight for prescribing information (revised: October2013). Available at: http://www.gilead.com/pdf/viread-pi.pdf. Accessed July 30, 2014.
7. Gallant JE, Staszewski S, Pozniak AL, et al.; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA. 2004;292:191-192.
8. Atripla: highlight of prescribing information. Available at: http://packageinserts. bms.com/pi/pi-Atripla.pdf. Accessed January 12, 2013.
9. Complera: highlight of prescribing information. Available at: http://www. gilead.com/pdf/complera-pi.pdf. Accessed January 12, 2013.
10. Stribild: highlight of prescribing information. Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2012/203100s000lbl.pdf002E Accessed January 12, 2013.
11. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808-816.
12. Chandwani S, Koenig LJ, Sill AM, et al. Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV. J Adolesc Health. 2012;51:242-251.
13. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739.
14. Hazra R, Balis FM, Tullio AN, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2004;48:124-129.
15. Aurpibul L, Cressey TR, Wittawatmongkol O, et al. Tenofovir pharmacokinetics when administered according to weight band dosing in HIV-infected children =15 kg receiving tenofovir/lamivudine/efavirenz once daily. In: 19th Conference on Retrovirus and Opportunistic Infection (CROI 2012), March 5-8, 2012. Seattle, Washington. [Abtsract no s-121].
16. Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278-283.
17. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43:595-612.
18. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2091-2096.
19. Kiser JJ, Fletcher CV, Flynn PM, et al.; Adolescent Trials Network for HIV/ AIDS Interventions. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2008;52:631-637.
20. Bouazza N, Urien S, Hirt D, et al. Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients. J Acquir Immune Defic Syndr. 2011;58:283-288.
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: http://www.aidsinfo. nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 12, 2014.
22. King JR, Yogev R, Jean-Philippe P, et al.; P1058 Protocol Team. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients. Antimicrob Agents Chemother. 2011;55:4290-4294.
23. Prasitsuebsai W, Kerr SJ, Thammajaruk N, et al. Pharmacokinetics of tenofovir in Thai adolescents using ritonavir-boosted protease inhibitor-based regimens. In: 20th Conference on Retrovirus and Opportunistic Infection (CROI 2013), March 3-6, 2013. Georgia, Atlanta. [Abstract no 973].
24. Pecora Fulco P, Kirian MA. Effect of tenofovir on didanosine absorption in patients with HIV. Ann Pharmacother. 2003;37:1325-1328.
25. Martinez E, Milinkovic A, de Lazzari E, et al. Pancreatic toxic effects associated with co-Administration of didanosine and tenofovir in HIV-infected adults. Lancet. 2004;364:65-67.
26. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003;37:e174-e176.
27. Kearney BP, Sayre JR, Flaherty JF, et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol. 2005;45:1360-1367.
28. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovircontaining first-line regimen. AIDS. 2012;26:1679-1684.
29. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189:837-846.
30. Gilead. Product monograph tenofovir disoproxil fumarate tablets 300 mg. Foster City, CA2012, Gilead Sciences, Inc., 2012. Available at: http://www. gilead.ca/pdf/ca/viread-pm-english.pdf. Accessed December 05, 2012.
31. Miller MD, Margot NA, Hertogs K, et al. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids. 2001;20:1025-1028.
32. Kulkarni R, Miller MD, White K. The contribution of HIV-1 reverse transcriptase resistance mutations to antiviral synergy and replication fitness in vitro. In: 6th Conference in HIV Pathogenesis and Treatment. July 17-20, 2011, Rome, Italy. [Abstract no. MOPE066].
33. Koga M, Kikuchi T, Nomura S, et al. A combinational mutation of K65R/ M184V/K103N/Y181C that makes HIV-1 highly resistant to TDF/emtricitabine/ efavirenz therapy significantly reduces viral replication capacity and which might be contributing to keep viremia at low-level in a patient with virological failure. In: 19th International AIDS Conference. July 22-27, 2012, Washington, DC. [Abstract no. TUPE045].
34. Sax PE, Tierney C, Collier AC, et al.; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230-2240.
35. Sax PE, Tierney C, Collier AC, et al.; AIDS Clinical Trials Group Study A5202 Team. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191-1201.
36. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes-A 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
37. Gallant JE, Staszewski S, Pozniak AL, et al.; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviralnaive patients: A 3-year randomized trial. JAMA. 2004;292:191-201.
38. Bergshoeff A, Burger D, Verweij C, et al.; PENTA-13 Study Group. Plasma pharmacokinetics of once-versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther. 2005;10:239-246.
39. Mallal S, Phillips E, Carosi G, et al.; PREDICT-1 Study Team. HLA-B 5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
40. Puthanakit T, Bunupuradah T, Kosalaraksa P, et al.; PREDICT Study Group. Prevalence of human leukocyte antigen-B5701 among HIV-infected children in Thailand and Cambodia: implications for abacavir use. Pediatr Infect Dis J. 2013;32:252-253.
41. Zucman D, Truchis Pd, Majerholc C, et al. Prospective screening for human leukocyte antigen-B. 5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr. 2007;45:1-3.
42. World Health Organization. Treatment if children living with HIV. Available at: http://www.who.int/hiv/topics/paediatric/en/index.html. Accessed December 27, 2012.
43. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al.; HIV STAR Study Group. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther. 2012;17:1351-1361.
44. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005;116:e846-e854.
45. Della Negra M, de Carvalho AP, de Aquino MZ, et al. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. Pediatr Infect Dis J. 2012;31:469-473.
46. Ross L, Elion R, Lanier R, et al.; COL40263 Study Team. Modulation of K65R selection by zidovudine inclusion: Analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/ zidovudine and tenofovir DF (study COL40263). AIDS Res Hum Retroviruses. 2009;25:665-672.
47. Gilead Sciences, Inc. U.S. Food and Drug Administration approves new formulations of Viread® for use by children living with HIV. Foster City, CA, Gilead Sciences, Inc., January 18, 2012. Available at: http://www.gilead. com/pr-1650180. Accessed November 25, 2012.
48. Saez-Llorens X, Castano E, Rathore M, et al. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in human immunodeficiency virus-1 infected children with virologic suppression. Pediatr Infect Dis J. 2015;34:376-382.
49. World Health Organization 2012. Technical update on treatment optimization: use of tenofovir disoproxil fumarate in HIV-infected children and adolescents aged 2-18 years: A public health perspective. Avaialble at: WHO web site: http://www.who.int/about/licensing/copyright-form/en/index. html.Accessed May 29, 2013.
50. Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: http://www.aidsinfo.nih.gov/guidelines/html/2/pediatric-Arv-guidelines/0. Accessed May 21, 2014.
51. World Health Organization 2013. Consolidated guideline on the use of antiretroviral drugs for treating and preventing HIV infection; reco mmendations for a public healt h approach. Available at: http://www.who.int/hiv/ pub/guidelines/arv2013/download/en/index.html. Accessed July 1, 2013.
52. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-Analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496-505.
53. Goicoechea M, Liu S, Best B, et al.; California Collaborative Treatment Group 578 Team. Greater tenofovir-Associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-Transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102-108.
54. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21:1273-1281.
55. Stöhr W, Reid A, Walker AS, et al.; DART Trial Team. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther. 2011;16:1011-1020.
56. Riordan A, Judd A, Boyd K, et al.; Collaborative HIV Paediatric Study. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J. 2009;28:204-209.
57. Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med. 2007;8:411.
58. Andiman WA, Chernoff MC, Mitchell C, et al.; PACTG iDACS 617 Study Team. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: Associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009;28:619-625.
59. Purswani M, Patel K, Kopp JB, et al.; Pediatric HIVAIDS Cohort Study. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32:495-500.
60. Viganò A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIVinfected children: A prospective, 96-week longitudinal study. Clin Drug Investig. 2007;27:573-581.
61. Judd A, Boyd KL, Stöhr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: A nested case-control study. AIDS. 2010;24:525-534.
62. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269-273.
63. Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol. 2006;21:1034-1036.
64. Viganò A, Bedogni G, Manfredini V, et al. Long-Term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: A 60-month follow-up study. Clin Drug Investig. 2011;31:407-415.
65. Aurpibul L, Narkbunnam T, Sirisanthana V, et al. 48-week safety of tenofovir when administered according to weight band dosing in HIV-infected children =15 kg as part of a once-daily HAART regimen. In: 20th Conference on Retroviruses & Opportunistic Infections. March 5-8, 2013. Georgia, Atlanta. [Abstract no v-112].
66. Puthanakit T, Siberry GK. Bone health in children and adolescents with perinatal HIV infection. J Int AIDS Soc. 2013;16:18575.
67. Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825-831.
68. Chavassieux P, Seeman E, Delmas PD. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev. 2007;28:151-164.
69. O'Brien KO, Razavi M, Henderson RA, et al. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr. 2001;73:821-826.
70. Jacobson DL, Lindsey JC, Gordon CM, et al.; Pediatric AIDS Clinical Trials Group P1045 team. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS. 2010;24:687-696.
71. Puthanakit T, Saksawad R, Bunupuradah T, et al. Prevalence and risk factors of low bone mineral density among perinatally HIV-infected Thai adolescents receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012;61:477-483.
72. Schtscherbyna A, Pinheiro MF, Mendonca LM, et al. Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents. Int J Infect Dis. 2012;16:e872-e878.
73. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711-e718.
74. Cassetti I, Madruga JV, Suleiman JM, et al.; Study 903E Team. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials. 2007;8:164-172.
75. Mirza A, Rathora M, Della Negra M, et al. Bone safety through week 144 of tenofovir disoproxil fumarate therapy in studies GS-US-104-0321 and GS-US-104-0352 in adolescents and children with HIV-1 infection. Pediatr Infect Dis J. 2014. In press.
76. Giacomet V, Mora S, Martelli L, et al. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40:448-450.
77. Purdy JB, Gafni RI, Reynolds JC, et al. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008;152:582-584.
78. Benhamou Y. Hepatitis B in the HIV-coinfected patient. JAIDS 2007; 45(suppl 2): S57-S67.
79. Konopnicki D, Mocroft A, de Wit S, et al.; EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593-601.
80. Piroth L, Sene D, Pol S, et al. Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY). AIDS. 2007;21:1323-1331.
81. Jain MK, Parekh NK, Hester J, et al. Aminotransferase elevation in HIV/ hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS. 2006;20:817-822.
82. Hoffmann CJ, Charalambous S, Thio CL, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS. 2007;21:1301-1308.
83. Omland LH, Weis N, Skinhoj P, et al. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIVinfected individuals: A nationwide cohort study. HIV Med. 2008;9:300-306.
84. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991;163:1138-1140.
85. Puoti M, Torti C, Bruno R, et al. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44(suppl 1):S65-S70.
86. Brook G, Main J, Nelson M, et al.; BHIVA Viral Hepatitis Working Group. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med. 2010;11:1-30.
87. Kosi L, Reiberger T, Payer BA, et al. Five-year on-Treatment efficacy of lamivudine-, tenofovir-And tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients. J Viral Hepat. 2012;19:801-810.
88. Matthews GV, Seaberg E, Dore GJ, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS. 2009;23:1707-1715.
89. Markowitz M, Zolopa A, Squires K, et al. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014;69:1362-1369.
90. Lanier ER, Ptak RG, Lampert BM, et al. Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-Type and nucleoside/nucleotide-resistant HIV. Antimicrob Agents Chemother. 2010;54:2901-2909.
91. Soler-Palacin P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25:171-176.
92. Pontrelli G, Cotugno N, Amodio D, et al. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. BMC Infect Dis. 2012;12:18.